# US 9,150,647 B2 · Biological inhibitors of ROR1 capable of inducing cell death

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,150,647 B2
- Document ID: US9150647B2
- Status: Granted
- Kind: B2
- Application number: 13/516,925
- Filed: 2010-12-10
- Published: 2014-01-02
- Granted: 2015-10-06
- Earliest claimed: 2009-12-18
- Assignees: Kancera AB
- Applicants: Hakan Mellstedt; Ingrid Teige
- Inventors: Hakan Mellstedt; Hodjattallah Rabbani; Ingrid Teige
- Web page: https://patentgrep.com/patent/US9150647B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C12N 2310/14: interfering nucleic acids [NA]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to antibodies and siRNA molecules for inducing cell death by the specific binding of ROR1, domains thereof of nucleotide molecules encoding ROR1. There are also provided methods involving and uses of the antibodies and siRNA molecules of the invention.

## Claims

### Claim 1

A biological inhibitor of ROR1 capable of inducing cell death in a cell expressing ROR1,
wherein the inhibitor is a monoclonal antibody, and wherein the extracellular domain to which the antibody binds has an amino acid sequence selected from the group consisting of YMESLHMQGEIENQI (SEQ ID NO: 3), CQPWNSQYPHTHTFTALRFP (SEQ ID NO: 4) and RSTIYGSRLRIRNLDTTDTGYFQ (SEQ ID NO: 2).

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a biological inhibitor of claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 3 (depends on 2)

A pharmaceutical composition as claimed in claim 2 which induces cell death in a cell expressing ROR1.

### Claim 4 (depends on 1)

A kit of parts comprising:
(i) a biological inhibitor as claimed in claim 1;
(ii) apparatus for administering the biological inhibitor; and
(iii) instructions for use.

### Claim 5 (depends on 1)

The biological inhibitor of claim 1, wherein the VH and VL regions of the antibody consist of the amino acid sequences shown in any one of FIGS. 17, 18 and 19 (SEQ ID NO:29 and SEQ ID NO: 31, SEQ ID NO: 33 and SEQ ID NO: 35, or SEQ ID NO: 37 and SEQ ID NO:39).
